Bullish case
$975 to $1,025
More likely if Dupixent keeps growing, EYLEA HD stabilizes retinal revenue, Libtayo and rare disease programs scale, late-stage pipeline data are positive, and investors pay about 18x forward earnings.
Regeneron Pharmaceuticals, Inc. research snapshot
REGN AI Stock Analysis
REGN AI stock analysis currently reads Regeneron Pharmaceuticals as a founder-led biotechnology company with strong Dupixent economics, a deep antibody and genetics platform, large cash and marketable securities, and material EYLEA franchise pressure. At the July 8, 2026 data cutoff, REGN closed near $676.23 with an implied market capitalization of about $68.80 billion. This page uses scenario ranges, technical levels, and source-backed facts. It is informational research, not investment advice.
Current price
$676.23
Market cap
$68.80 billion
AI score
70 / 100
Rating
High-quality founder-led biotech with product-cycle risk
Trend status
Long-term trend positive, short-term setup mixed after a sharp rebound
Data cutoff (updated weekly)
July 8, 2026
Informational use only. This page is not investment advice.
Research quality check
- information Richness
- A-level information richness. Regeneron has decades of public filings, detailed earnings releases, clinical pipeline disclosures, third-party financial datasets, and active analyst coverage.
- bias Check
- The main AI bias risk is copying the consensus that Dupixent and pipeline breadth offset EYLEA erosion without testing competition, drug-pricing policy, trial failure, manufacturing disruption, and capital allocation risk.
- ai Confidence
- High for reported revenue, EPS, balance sheet, market cap math, and current technical references. Medium for forward scenarios because biotech value can reprice around clinical, FDA, reimbursement, and patent events.
- investment Certainty
- Medium. The business quality is above average, but the investment case depends on EYLEA HD stabilization, continued Dupixent growth, pipeline conversion, and a reasonable earnings multiple.
Quick verdict table
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | Regeneron monetizes biologic science through approved medicines, Sanofi collaboration revenue, in-house product sales, and a large clinical pipeline. | High |
| Moat | The moat comes from antibody discovery, genetics data, patents, biologics manufacturing, clinical know-how, physician trust, and collaboration scale. | Medium-high |
| Management | Founder CEO Leonard Schleifer and founding scientist George Yancopoulos remain central to the culture, pipeline, and capital allocation record. | Medium-high |
| Financial trend | FY2025 revenue grew 1% to $14.343 billion, while Q1 2026 revenue grew 19% to $3.605 billion and non-GAAP EPS grew 15%. | High |
| Valuation | At $676.23, REGN traded near 16.5x TTM EPS, 4.6x sales, 2.2x book value, and 16.9x free cash flow per share using verified inputs. | Medium-high |
| Technical trend | ChartMill rated the long-term trend up and short-term trend neutral, with RSI near neutral and MACD negative after the rebound. | Medium |
| Risk level | Key risks are EYLEA competition, drug-pricing agreements, FDA and clinical setbacks, pipeline concentration, manufacturing issues, and leadership succession. | Medium-high |
| AI confidence | High for descriptive research and calculations, lower for exact price outcomes because biotech event risk is nonlinear. | High data confidence |
| Investment certainty | Medium certainty. REGN is a high-quality biotech, but a buy decision depends on price discipline and confidence in the post-EYLEA growth bridge. | Medium |
REGN AI stock forecast
REGN AI Stock Forecast Scenarios
The REGN AI stock forecast uses scenario math around the $676.23 quote and FY2025 non-GAAP diluted EPS of $44.31. The audited three-year framework produced a bearish area near $380, a base area near $726, and a bullish area near $1,005 before dividends.
Base case
$700 to $750
More likely if earnings compound at low single digits, EYLEA pressure remains manageable, cash returns continue, and the market values REGN near a mid-teens earnings multiple.
Bearish case
$360 to $400
More likely if EYLEA erosion accelerates, fianlimab or other late-stage programs disappoint, drug-pricing policy reduces net price, or the market compresses REGN toward a low-teens multiple.
REGN AI technical analysis
REGN AI Technical Analysis
REGN AI technical analysis is constructive but not clean as of the July 8, 2026 cutoff. StockAnalysis listed the stock at $676.23, with a 50-day moving average near $653.81, a 200-day moving average near $700.73, and RSI near 65.77. ChartMill described the long-term trend as up, the short-term trend as neutral, and MACD as negative.
| Level | Value | Why it matters |
|---|---|---|
| Current price | $676.23 | July 7, 2026 close used for the July 8, 2026 data cutoff and market cap math. |
| Near support | $654 to $654 | The 50-day moving average near $653.81 is the first trend support area after the rebound. |
| Secondary support | $610 to $611 | ChartMill listed an important trend-line support area near $610.58. |
| Deep support | $542 to $543 | ChartMill listed a lower horizontal support zone near $542.52. |
| Resistance | $696 to $701 | The $700 area lines up with the 200-day moving average and recent resistance around the high-$690s. |
| Upper resistance | $796 to $805 | ChartMill listed resistance near $796.56 and a broader upper zone near $804.53. |
| Momentum | RSI 65.77, MACD negative | Momentum is improving but not decisive because RSI is elevated while MACD remained negative in the ChartMill snapshot. |
| Volume | 20-day average near 1.08 million shares | Volume spikes should be checked against FDA decisions, earnings, EYLEA updates, and pipeline data. |
| Volatility | Low beta, high event sensitivity | StockAnalysis listed beta near 0.24, but biotech-specific clinical and regulatory events can still create sharp single-stock moves. |
| Invalidation | Close below $654, then $610 | A break below the 50-day average weakens the rebound. A break below the $610 area would force a fresh thesis review. |
REGN AI trading strategy
REGN AI Trading Strategy Framework
The REGN AI trading strategy is a rules-based framework for a cash-rich large-cap biotech with patent-cycle pressure and pipeline optionality. It is not personal advice and should be paired with live quotes, position sizing, FDA calendars, earnings releases, and risk limits.
Trend-following setup
Watch for REGN to hold above the 50-day moving average and reclaim the 200-day moving average with confirming volume and no negative EYLEA, FDA, or trial news.
A close below the $654 area should reduce trend confidence. A close below $610 should invalidate the swing setup and trigger a fundamental review.
Mean-reversion setup
If REGN pulls back toward $654 or $610 without a new product, pricing, or trial problem, compare the drawdown with Dupixent growth, EYLEA HD traction, cash flow, and buyback support.
Do not average down through drug-specific bad news. Patent, FDA, reimbursement, or manufacturing issues can turn a chart level into a business-level break.
Fundamental monitor
Track Dupixent global net sales, EYLEA and EYLEA HD U.S. sales, Libtayo growth, fianlimab data, cemdisiran and garetosmab decisions, R&D spend, buybacks, dividends, and cash plus marketable securities.
Lower confidence if EPS growth depends mainly on marketable-security gains, multiple expansion, or buybacks rather than product growth and pipeline conversion.
Investment research summary
Four-master Research Compression
Business essence
Regeneron converts science, clinical proof, biologics manufacturing, regulatory approvals, and partner commercialization into medicine revenue and collaboration economics.
Moat
The moat is strongest where VelociSuite technology, human genetics, biologics expertise, patents, trial execution, manufacturing scale, and prescriber trust reinforce each other. It weakens when a patent expires, a rival drug is better, or a payer forces price concessions.
Munger risk inversion
The thesis fails if EYLEA and EYLEA HD decline faster than Dupixent and newer products grow, if late-stage trials fail, if drug-pricing policy hits net prices, or if founder-led scientific culture becomes hard to replicate.
Management
Leonard Schleifer and George Yancopoulos built Regeneron around internal discovery and long-cycle R&D. The next test is whether capital allocation, succession planning, and pipeline choices keep returns high after the original leadership era.
Industry trend
Large-cap biotech benefits from aging populations, biologics innovation, genetics data, oncology, immunology, and rare disease demand, but faces patent cliffs, payer scrutiny, biosimilars, FDA risk, and binary clinical outcomes.
Valuation and margin of safety
REGN is valued as a durable but challenged biotech, not as a no-risk compounder. Margin of safety depends on whether the market is underpricing cash, Dupixent economics, and pipeline depth or correctly discounting EYLEA and policy risk.
Source-backed data
REGN Data Table
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| REGN price | $676.23 close on July 7, 2026 | StockAnalysis quote and statistics | July 8, 2026 |
| Market capitalization | $68.80 billion, verified as $676.23 x 101.74 million shares | financial_rigor.py market cap verification | July 8, 2026 |
| FY2025 revenue | $14.343 billion | Regeneron FY2025 release, StockAnalysis, and Macrotrends | July 8, 2026 |
| FY2025 GAAP net income | $4.505 billion | Regeneron FY2025 release | July 8, 2026 |
| FY2025 non-GAAP diluted EPS | $44.31 | Regeneron FY2025 release | July 8, 2026 |
| Q1 2026 revenue and non-GAAP EPS | $3.605 billion revenue, $9.47 non-GAAP diluted EPS | Regeneron Q1 2026 earnings release | July 8, 2026 |
| Dupixent and EYLEA franchise data | Q1 2026 Dupixent global sales up 33% to $4.9 billion; total EYLEA HD and EYLEA U.S. sales down 10% to $941 million | Regeneron Q1 2026 earnings release | July 8, 2026 |
| Cash and marketable securities | $18.540 billion at March 31, 2026; long-term debt $1.986 billion | Regeneron Q1 2026 Form 10-Q | July 8, 2026 |
| Share count and ownership | 101.74 million shares outstanding; insiders 3.82%; institutions 89.73% | StockAnalysis statistics | July 8, 2026 |
| Valuation ratios | 16.5x TTM EPS, 4.6x sales, 2.2x book, 16.9x free cash flow per share | financial_rigor.py valuation verification | July 8, 2026 |
| Technical snapshot | 50-day MA $653.81, 200-day MA $700.73, RSI 65.77; ChartMill long-term trend up and short-term trend neutral | StockAnalysis and ChartMill technical data | July 8, 2026 |
Frequently Asked Questions
Read the AMGN AI stock analysisView the MRK AI stock forecastExplore the AI Stock PickerBuild an AI trading strategy
This REGN AI stock analysis is an informational research tool only. It is not investment advice, financial advice, a recommendation, or a guarantee of future returns. Forecast scenarios are based on available public data as of July 8, 2026 and can be wrong.